Common side effects include pain at the injection site: Aluminium in vaccines

Far from being a relatively harmless vaccine ingredient, aluminium in vaccines has and is creating a long term legacy as it accumulates in our bodies. Its not just that vaccine recipients might experience pain at the injection site that can be relieved with a hot towel (actual advice), but that vaccine material persists at the injection site indefinitely – and aluminium is the culprit.
​
Vaccine antigens are absorbed on to aluminium salts to 'promote and prolong an immune response' and a quick online search will certainly reassure you that it's 'perfectly safe' . That's the spiel anyway. Here is a summary of some historical and alarming research -

• It doesn't actually work - The mechanism of action is unclear and experimental studies show that the vaccine antigens (virus or bacteria) disappear within a few hours, despite adding aluminum to vaccines for the last 90 years.
• The amounts added far exceed any recommended safe level - by up to 1000 times.
• It is nearly 20 years since aluminium was 'put on trial' by some 70 scientists who gathered to discuss a mysterious muscle ailment - Macrophagic myofasciitis syndrome or MMS. It is diagnosed from muscle biopsies where injections have been given and they show aluminium hydroxide present. The symptoms include muscle and joint pain, fatigue and in some cases serious neurological diseases such as Multiple Sclerosis.
• Aluminium from vaccines has been found to be present at the injection site up to 8 years after the vaccine had been administered. (That study, like the MMS discussion, was conducted in 2000.)

In 2013 a British Medical Journal case study described a child with a persistent nodule or granuloma on the front of a thigh which was eventually excised to resolve the issue. (Granuloma - a mass of granulation tissue, typically produced in response to infection, inflammation, or the presence of a foreign substance).
​
So injecting vaccines and then cutting out the residue is actually a thing. Alarmingly, as I delved further, the strategy to minimise the risk is to inject the vaccine in two lots in two separate limbs and effectively halve the impact.  I'm quite sure that would be problematic given that the current schedule calls for several aluminium containing vaccines to be administered at once, never mind the existing issue of how to hold down a child long enough to get the job done.

The case study shared the following enlightening observations -

• Intensely itching subcutaneous nodules (granulomas) may appear at the injection site for aluminium containing vaccines and persist for many years.
• The nodules can appear a remarkably long time after vaccination (months or even years).
• Most patients with vaccine-induced itching nodules have become contact allergic to aluminium.
• The condition is poorly recognised in Health Care which may lead to prolonged symptoms and unnecessary investigations.

So what is the legacy for our children?  Every limb being injected multiple times over the course of childhood and adolescence? Will they be able to lift their arms or move around when they are adults?

So nothing is done, nothing changes and the burden grows. The only way to not be alarmed is to stop researching!  But then there was this, also 2017 -
​
“The unequivocal neurotoxicity of aluminum must mean that when brain burdens of aluminum exceed toxic thresholds that it is inevitable that aluminum contributes toward disease. Aluminum acts as a catalyst for an earlier onset of Alzheimer’s disease in individuals with or without concomitant predispositions, genetic or otherwise. Alzheimer’s disease is not an inevitable consequence of aging in the absence of a brain burden of aluminum.'

We need to plan for a future of forgetful incapacitated people..
​
(Full references available)
Nokleby H, Expert Rev Vaccines 2007;6(5):863-869
Vaccination? It’s your informed choice, Dr Peter Baratosy, 2004
Science, 26 May 2000:Vol. 288, Issue 5470, pp. 1323-1324
Malakoff D, Science 2000, May 26;288(5470):1323-1324
BMJ Case Rep. 2013; 2013: bcr2012007779.
​Published online 2013 Jan 24. 
Journal of Alzheimer's Disease Reports, vol. 1, no. 1, pp. 23-25, 2017

​KS